This article gives visibility beyond the FY27 1000cr Guidance from the management , anyone having a view on this ?
6 Likes
Supriya Lifesciences seems to be at an inflection point after years of platform building-the company appears ready to sweat assets and scale outcomes.
Over FY22–FY26, Supriya has executed one of the largest capacity + capability builds in its history. The Ambernath capex materially expanded API capacity (multiple blocks, higher reactors, backward integration), while keeping gross debt negligible and net cash broadly intact. Even at peak capex, D/E stayed <0.2x, with operating cash flows funding growth rather than leverage.
What makes this phase interesting is that capacity is now largely built. Incremental growth here is asset-light in nature—higher utilisation, richer mix, and operating leverage kicking in.
On the capability front, the company has quietly widened its addressable opportunity set.
From being a pure-play API exporter (70+ APIs), Supriya has added Formulations, Nutraceutical ingredients, and early-stage CDMO services—all built on the same chemistry backbone. New launches over the last 6–8 quarters have consistently been higher value, complex, and customer-specific, moving away from commoditised APIs.
Access has improved meaningfully.
The company today holds USFDA, EU-GMP, ANVISA (Brazil), COFEPRIS (Mexico) and other LatAm/ROW approvals, giving it front-row access to regulated markets. >85% of revenues are export-led, with a diversified customer base across US, Europe and LatAm, reducing single-market risk.
The CDMO optionality is the real kicker.
Management commentary suggests multiple custom synthesis / contract manufacturing discussions—initially small, but high-margin, sticky, and scalable. If even 1–2 programs transition from development to commercial supply, revenue and margin trajectories can change meaningfully, similar to what differentiated Indian API leaders experienced in their early CDMO days.
Execution credibility matters—and here Dr Saloni Wagh stands out.
A technocrat-promoter with deep process chemistry focus, conservative capital allocation, and consistent communication, she has prioritised ROCE, compliance, and long-term customer trust over short-term topline optics. This shows in stable EBITDA margins (~30%+ through cycles) and a clean balance sheet even post heavy capex.
The setup increasingly resembles an early-stage compounding platform, not a single-cycle API story.
If Supriya can (a) ramp Ambernath utilisation, (b) scale higher-value launches, and (c) land quantum jumps via CDMO, the company has a credible path to multiplying size without proportionate capital.
In that sense, it is not unreasonable to view Supriya as a potential Divi’s Laboratories-in-the-making—not in scale today, but in philosophy: chemistry depth, balance-sheet discipline, and customer-led growth.
13 Likes
Capex is in final phase. Revenue start reflecting from Q4.
3 Likes
In January this year, the Chinese regulator NMPA announced a ban on Supriya’s API Chlorpheniramine Maleate on account of failure to meet the required quality standards. Yet there was no mention of this in the Q3 concall at all. Neither the management mentioned it, nor was there any question from the analysts. This, despite China getting discussed multiple times during the concall. I find this very surprising. Supriya management never fails to mention that they are competing in the market against the Chinese, and customers prefer them over “low quality” Chinese products. And here, the Chinese regulator bans Supriya for quality deficiencies!
China now forms a very small portion of the company’s current revenues, so the direct financial impact of this ban is not significant. But, for a company aspiring to become a CMO / CDMO partner to large pharma multinationals, a ban like this is quite an embarrassment. Not sure why this did not get discussed in the call. Or am I missing something here?
13 Likes
When a company is banned in a major market like China for fundamental hygiene and batch-compliance failures, it often triggers “for cause” inspections by other regulators.
2 Likes
If Chinese regulator NMPA banned Supriya ‘s API, it must have been reported by management. And if there were no questions asked in concall then you can’t fault the management. Supriya management has a relatively clean image. So we should not jump to conclusions.
2 Likes
There is NO communication / announcement from Supriya Lifescience on NMPA issuing Ban. Reply/Clarification was needed especially after regulator described facility’s management as “lax” and without effective measures in place to prevent pest and animals from entering. (It is important to note that Supriya has faced similar issue in past in 2020 also.)
3 Likes
Excuse me. These kinds of comments against a professional pharmaceutical company appears to be roadblocks/hindrances. Is it Chinese ploys to kill competition for Chinese companies?
But if the issue is not reported by Supriya, then it is certainly a red flag and raises compliance issues. Why no action is taken by BSE/NSE ?
Supriya Lifesciences: Q3FY26 Conference Call Summary
- Financials:
Q3FY26:
Revenue - 206Cr vs 186Cr, 11% growth Y-on-Y
EBIDTA - 77Cr vs 66Cr, growth of 9% Y-on-Y, EBIDTA margin - 35%
PAT - 50Cr vs 47Cr, PAT margin: 24.1%
9MFY26:
Revenue - 551Cr vs 512Cr, 8% growth Y-on-Y
EBIDTA - 196Cr vs 193Cr, growth of 1.7% Y-on-Y, EBIDTA margin - 36%
PAT - 135Cr vs 138Cr, down 2%, PAT margin: 24.1% - Capex Q3FY26 - 28Cr, 9M FY26 - 71 crores. Rest of FY26 - 15Cr for maintenance majorly.
- We haven’t utilized any of our working capital limits except for BG and LOC.
- Export contributed 82% of the revenue.
New launches and pipeline:
- We have successfully launched a key cardiovascular product in Q3FY26, expected to contribute meaningfully from Q4FY26.
- We also launched our ADHD product which we expect to scale up over the coming quarters.
- Our liquid anesthetic product has been commercialized with steady monthly supplies underway.
- The development activities for our contrast media product continue to progress as planned. The facility is ready for capitalization. This is a key milestone for our CDMO segment. We will capitalize the site in Q4FY26.
- We have planned a launch of 3-4 products each year.
- We filed the USDMF and CEP for a CVS product in Q3FY26.
- We have successfully launched about three products in the first three quarters and expect to launch our fourth contrast media product in Q4. We expect to target 3 to four products for the next few years, and their contribution would be about 10% in the next 2 to 3 years because for any new product it takes about 2 to 3 years to scale up in regulated markets.
Guidance:
- Our progress towards the rupees 1,000 crore revenue milestone for financial year 27 remains on course.
- We should be able to grow 20%+ for next 5 years comfortably.
- Guidance for FY26: We are confident of achieving 20% guidance for FY26 with an EBIDTA margin of 33-35% and a large part would come in Q4. This is based on the order book visibility we have. Following are the reasons for delay in scale up:
a. For some of the new launches of Q1 and Q2 of this year, scale up and the regulatory approvals—all that activity we have done in the first three quarters. So, a larger contribution from these newly launched products you’ll be able to see in Q4.
b. Holiday season post 15th December in LATAM and Europe did push the deliveries to Q4FY26.
Growth driver for 1000Cr revenue in FY27:
a) Scale up of new products in regulated markets.
b) New product launches. Every year we launch 3-4.
c) Ambernath formulation factory commissioning in Q4.
Capex:
- Ambernath: Capex will be 140-160cr. 2.5x asset turn expected.
- Isambay site: EC is approved and we are working on the blueprint. Another 9-12 months before more details can be finalized and shared.
- FY27 Capex - 40-50Cr to start with. After that we need to figure out. From FY29 point of view we might need at least one facility at Patalganga either API or Formulation.
Q&A
- Cardiovascular product: The visibility of 300T is intact. The successful scale up in Q3 ensure higher volume in coming quarters.
- A21 Site usages (The A21 site is a land parcel adjacent to the company’s main manufacturing complex at Lote Parshuram Industrial Area, M.I.D.C., Tal. Khed, Dist. Ratnagiri, Maharashtra):
a. Protein business
b. Warehouse for RM - Protein project: It’s a very new formulation in the Indian market. A lot of the formulators are still doing R&D which is expected to be completed in next 3-4 months. Once the R&D part is cleared, then the formulators would be ready to start buying commercially and launch their products. For export market we have supplied our samples in Australia and some Southeast Asian countries like Philippines, Malaysia, and Singapore from where we are getting good traction. Protein project is making progress, but any significant revenue contribution would still take a couple of more quarters.
- EU FTA Deal: There is not much change wrt pharma in EU FTA deal, hence no impact on the company.
- DSM project:
a. Pharma validation completed last month. FY27 will have full contribution of the order of 60Cr.
b. DSM partnership has opened doors for us to talk to a lot of larger companies. We are talking to several where we want to be in partnership for advanced intermediates or API supply. Hopefully, one or two we should be able to announce soon.
c. We will have small revenue coming in at Q4FY26 itself, but meaningful revenues will come from next financial year. It will be EBITDA positive somewhere around Q3FY27. - Restriction on ATS-8 import by Indian government:
a, It’s only applicable to formulators who want to sell it in Indian market. Our customers are export oriented. Also, we can comfortably compete the Chinese prices as we are fully backward integrated. Trials are done at a large user site. We will get a large chunk of their orders. We don’t have firm annual contract, but we are in signing stage for volume commitments.
b. We have a fully backward integrated process developed and identified where we will be doing the ATS3 to ATS5 conversion. Commercially, that process should start maybe by next month itself. - Regulatory Inspection: EU cGMP inspection at Ambernath: It should happen in next 3-4 months.
- Backward Integration: We are fully backward integrated for almost 74% of our total revenue today and that number will go up to 80 to 82% as soon as some of the new product commercial launches are completed.
- Ambernath site:
a. It will be commissioned in Q4FY26. It will be major contributor for CMO. Regulatory approval for this site is important so that we start gaining traction of volume in regulated markets.
b. We are targeting EU audit first because the larger market is in Europe and then the USFDA audit. Full effect will only be in FY27. - On GLP1 - Our main focus is on the finished formulation on the injectable side as well as on the tablet side from Ambernath. Validation batches are in progress for the injection as we speak and once the approvals for the facility come in we can start seeing some volume traction in markets like Russia and the Middle East where the product is not under patent.
- Cancer detection kit: It’s a novel product. The innovator is still in discussion for the drug approval as it is part drug and part medical equipment. Once the approval is done, then we will look at commercial viability.
- CDMO/CMO projects:
a. CMO/CDMO and new product launches should be 20% of the turnover.
b. We do have a couple of large contracts under discussion and I’m very hopeful that in the coming few quarters we’ll be able to announce some. We are still in the term sheet signing stage.
c. The gestation period for CDMO activities is long. We have successfully set up our Ambernath R&D which is working on finished formulations and API R&D. We are now targeting specific customers and markets. Innovator tie-up is an area we intend to do soon, and we have a technical lead at the senior management level focusing on these opportunities. As of now on the CDMO front we have nothing specific in our hand; most opportunities are on the contract manufacturing side. A firm strategy on CDMO will only be shared in the next couple of quarters once we have one
Others:
a. Roboflavin has moved to a new block. Next 6-7 months this block will be completely freed up and will be utilized for some of the new products like ADHD, anesthetic product and contrast media products.
b. When you typically introduce any new product into the portfolio, the first scale-up will happen in semi-regulated markets where the margins are slightly lower as compared to when it scales up in a regulated market. Guidance of margin at 33 to 35%.
c. We have steady demand across core therapeutic segments including anesthetic, anti-diabetic, anti-anxiety, vitamins, and ADHD.
Disc: Invested since last couple of years. The details above are based on my understanding. I might have misunderstood some portions. Please refer to the confcall for perfect understanding.
8 Likes
There is more to this. Chinese regulator NMPA on same date of 27 Jan 2026 ban a Sun pharma product also. Found out that inspection made over remote basis and conclusion made that Sun process is not adequate. Strangely Sun also did not came up with announcement in BSE and NSE.
1 Like
Yes, I saw that. That is why I ended by asking - am I missing something. Perhaps institutional investors know something we don’t. My point was not just the regulator’s action but the lack of discussion about it in the concall, though the price spoke! The stock came down from Rs.750 to 650 after the announcement.
I think it will be good idea to email the company rather than just speculating as no body is sure about the quantum of impact this ban has on the company.
Regards
Raj
3 Likes
ICRA has withdrawn the rating.
What does it mean generally if the ratings are withdrawn.
Is that positive news or Negative news
Can anyone please throw light on this
Regards,
Saravanan R
The withdrawal itself is neutral.
Typical reasons companies withdraw ratings:
-
low borrowing
-
unused bank limits
-
reduce rating surveillance cost
-
internal funding.
Since leverage is extremely low, external rating becomes less relevant. so the company asked to withdraw it.
Supriya’s decision to withdraw its credit ratings, (although banks have given NOC), is a behavioral signal that often points to lack of transparency or can say shift in corporate strategy that may not favor us minority shareholders. One can argue, Credit rating agencies (CRAs) are reactive to regulatory shocks. Following the NMPA’s “lax management” finding, ICRA would have been forced to review the “Positive” outlook.
Disc: biased as exited on NMPA news!
Supriya is covered by India Ratings.
Regards,
Raj
This is mentioned in Last India Rating report, which should be read with news of NMPA report on Supriya of Jan end…..
Regulatory Risk: The regulated markets such as the Europe and US contributed around 40% to SLL’s total sales in FY25. SLL has one USFDA-approved facility at Lote Parshuram, Maharashtra, spans 33,000 square metre across five therapy-based blocks. The facility holds accreditations from global regulatory bodies, including USFDA, EDQM, AIFA, TGA, KFDA, NMPA, and COFEPRIS, ANVISA and Health Canada. Ind-Ra highlights SLL had a strong regulatory track record historically. As of November 2025, none of the company’s manufacturing sites have outstanding regulatory or compliance issues with any other regulatory agency. Ind-Ra highlights that non-compliance or data integrity issues with any manufacturing facility might affect new product approvals from several regulatory agencies or could lead to the shutdown of the facility.
An approval revocation (from NMPA) is a sign of concern for shareholders, especially given China is a major market for that API for Supriya. But the lack of activity or management talk on this matter (similar for Sun Pharma), has me actually thinking on the importance of this revocation. Nonetheless, the true test would be the next regulatory check from one of USFDA, EDQM, AIFA, TGA, KFDA, COFEPRIS, ANVISA or Health Canada for that same facility considering some of these would have a more stringent criteria than NMPA.
2 Likes
Came across this interview with Dr. Wagh where he mentions USFDA audited their plant in Jan 2026 within a 48 hrs notice and was successful (EIR letter is yet to be posted). Timeline wise this is barely couple of weeks prior to NMPA letter.
If USFSA audit is cleared without a scratch, how much do we trust NMPA ban?
Interview with Dr. Wagh: Supriya Lifescience ramps up capacity and global readiness for next phase of growth - Express Pharma
Also, a great post on Supriya’s business approach and current status: Winning Without War: A Path to Niche Dominance
Disc: Invested
1 Like
(post deleted by author)
1 Like